Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing

Clinical and Vaccine Immunology

Volumn 16, Issue 9, 2009, Pages 1327-1331

  Pavlov, Igor ^a   Martins, Thomas B ^a   Delgado, Julio C ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT ANTIGEN;

ACCURACY; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLUORESCENT MICROSPHERE IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; LEISHMANIA; MALE; PLASMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SERUM; SUPERNATANT; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, CD30; CULTURE MEDIA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOASSAY; MALE; MICROSPHERES; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TH2 CELLS; YOUNG ADULT;

EID: 69749102949     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00047-09     Document Type: Article

References (23)

1. Ajdary, S., R. Jafari-Shakib, F. Riazi-Rad, and A. Khamesipour. 2007. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J. Infect. 55:75-78. (Pubitemid 46888069)
2. Ajdary, S., F. Riazi-Rad, R. Jafari-Shakib, and M. Mohebbali. 2006. Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity. Clin. Exp. Immunol. 145:44-47.
3. Box, G. E. P., and D. R. Cox. 1964. An analysis of transformations. J. R. Stat. Soc. Ser. B 26:211-252.
4. Breen, E. C., S. Fatahi, M. Epeldegui, W. J. Boscardin, R. Detels, and O. Martinez-Maza. 2006. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol. 27:187-194.
5. Caligaris-Cappio, F., M. T. Bertero, M. Converso, A. Stacchini, F. Vinante, S. Romagnani, and G. Pizzolo. 1995. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin. Exp. Rheumatol. 13:339-343.
6. Chowdhury, F., A. Williams, and P. Johnson. 2009. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 340:55-64.
7. Ciferská, H., P. Horak, Z. Hermanova, M. Ordeltova, J. Zadrazil, T. Tichy, and V. Scudla. 2007. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin. Rheumatol. 26:723-728.
8. Del Prete, G., M. De Carli, M. M. D'Elios, K. C. Daniel, F. Almerigogna, M. Alderson, C. A. Smith, E. Thomas, and S. Romagnani. 1995. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J. Exp. Med. 182:1655-1661.
9. Hansen, H. P., A. Recke, U. Reineke, B. Von Tresckow, P. Borchmann, E. P. Von Strandmann, H. Lange, H. Lemke, and A. Engert. 2004. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J. 18:893-895.
10. Horn-Lohrens, O., M. Tiemann, H. Lange, J. Kobarg, M. Hafner, H. Hansen, W. Sterry, R. M. Parwaresch, and H. Lemke. 1995. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int. J. Cancer 60:539-544.
11. Isenberg, D. A., J. J. Manson, M. R. Ehrenstein, and A. Rahman. 2007. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 46:1052-1056.
12. Kadin, M. E. 1986. Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases. Arch. Dermatol. 122:1388-1390.
13. Kellar, K. L., R. R. Kalwar, K. A. Dubois, D. Crouse, W. D. Chafin, and B. E. Kane. 2001. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 45:27-36.
14. Munoz, L. E., U. S. Gaipl, and M. Herrmann. 2008. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun. Rev. 7:594-597.
15. Nishioka, C., S. Takemoto, S. Kataoka, S. Yamanaka, T. Moriki, M. Shoda, T. Watanabe, and H. Taguchi. 2005. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci. 96:810-815. (Pubitemid 43019832)
16. Pelzl, S., G. Opelz, V. Daniel, M. Wiesel, and C. Süsal. 2003. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75:421-423. (Pubitemid 36222975)
17. Romagnani, S. 1995. Role for CD30 antigen in human T helper 2-type responses. Ciba Found. Symp. 195:55-62.
18. Schwab, U., H. Stein, J. Gerdes, H. Lemke, H. Kirchner, M. Schaadt, and V. Diehl. 1982. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299:65-67. (Pubitemid 12049770)
19. Shapiro, S., and M. B. Wilk. 1965. An analysis of variance test for normality (complete samples). Biometrika 52:591-611.
20. Stein, H., J. Gerdes, U. Schwab, H. Lemke, and V. Diehl. 1983. Evidence for the origin of Hodgkin and Sternberg-Reed cells from a newly detected small cell population. Haematol. Blood Transfus. 28:407-410.
21. Süsal, C., S. Pelzl, B. Dohler, and G. Opelz. 2002. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J. Am. Soc. Nephrol. 13:1650-1656.
22. Visco, C., G. Nadali, T. P. Vassilakopoulos, V. Bonfante, S. Viviani, A. M. Gianni, M. Federico, S. Luminari, P. Peethambaram, T. E. Witzig, G. Pangalis, F. Cabanillas, L. J. Medeiros, A. H. Sarris, and G. Pizzolo. 2006. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur. J. Haematol. 77:387-394.
23. Wilcoxon, F. 1945. Individual comparisons by ranking methods. Biometrics Bull. 1:80-83.